Overview

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100
Phase:
Phase 1
Details
Lead Sponsor:
BioVersys AG
Collaborators:
CRU Hungary Early Phase Unit
CRU Hungary Kft
Treatments:
Rifabutin